Evidence map›Paper›PMID 30622543›Full record

ArticleFrontiers in immunology2018

A Possible Reason to Induce Acute Graft-vs.-Host Disease After Hematopoietic Stem Cell Transplantation: Lack of Sirtuin-1 in CD4

Ya-Jing Xu, Fang-Ping Chen, Yan Chen, Bin Fu, En-Yi Liu, Lang Zou, Lin-Xin Liu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. The absence of AhR in CD4Clinical epigenetics · 2022
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Ya-Jing XuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, China.
Fang-Ping ChenDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, China.
Yan ChenDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, China.
Bin FuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, China.
En-Yi LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, China.
Lang ZouDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, China.
Lin-Xin LiuDepartment of Hematology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sirtuin 1 (SIRT1) is a critical suppressor of T cell immunity. However, whether SIRT1 is involved in the progression of acute graft-vs.-host disease (aGVHD) has still remained unclear. PI3K/Akt/mTOR pathway is a crucial element involved in the activation and functions of T cells. Over-activation of PI3K/Akt/mTOR signaling may be related to the occurrence of aGVHD. STAT3 activation requires phosphorylation and acetylation. A recent study showed that STAT3 hyperphosphorylation in CD4

Indexed as

AcetylationAdultCD4-Positive T-LymphocytesFemaleGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHumansMaleMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesPhosphorylationSignal TransductionSirtuin 1STAT3 Transcription FactorTOR Serine-Threonine KinasesMAP Kinase Kinase Kinase 7MAP Kinase Kinase KinasesMTOR protein, humanSIRT1 protein, humanSirtuin 1STAT3 protein, humanSTAT3 Transcription FactorTOR Serine-Threonine KinasesaGVHDIL-1β signalingmTOR pathwaySIRT1Th17

Identifiers

PMID30622543
PMCPMC6308326
OpenAlexW2906206869

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.